Has any company published a product‑level clinical trial for Memo Blast or similarly named brain supplements?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
No evidence in the supplied reporting shows a company has published a product‑level, peer‑reviewed clinical trial for a consumer brain‑supplement called “Memo Blast” (or a similarly named over‑the‑counter nootropic); the only rigorous clinical trial publications in the material provided relate to Memo Therapeutics’ monoclonal antibody potravitug for BK polyomavirus in kidney transplant patients, a prescription biologic — not a dietary supplement — and those Phase I/II reports are company announcements and journal publications about a drug candidate [1] [2] [3].
1. The name overlap that breeds confusion: supplement marketing versus biotech publications
Multiple press and corporate releases in the provided dataset document Memo Therapeutics AG’s clinical trial program for potravitug — including published Phase I safety/tolerability/PK data and company announcements of Phase II results and presentations — clearly about a monoclonal antibody developed for BK polyomavirus in kidney transplant recipients [2] [1] [3], while the only mention of a “Memo Blast” appears on a consumer review site discussing product performance and guarantees, with no citation of clinical trial data [4], which creates a high risk that readers will conflate supplement marketing copy with bona fide biotech trial publications.
2. What the clinical literature in these sources actually shows — a drug, not a supplement
Memo Therapeutics’ publications and press releases describe first‑in‑human, randomized, placebo‑controlled Phase I work and a randomized, double‑blind, placebo‑controlled Phase II (SAFE KIDNEY II) for potravitug involving about 90–95 patients across U.S. sites, with Phase I appearing in Clinical and Translational Science and Phase II topline results and conference presentations referenced in company releases and industry outlets [2] [1] [3] [5]. Those are product‑level, peer‑reviewed (Phase I) and company‑reported (Phase II) clinical trials — but they concern a therapeutic monoclonal antibody for a transplant infection, not an over‑the‑counter cognitive supplement branded “Memo Blast” [2] [1].
3. The absence of evidence for Memo Blast clinical trials in the provided reporting
The consumer‑oriented “Memo Blast” appears only in an unattributed health‑review page that comments on user feedback, guarantees and inconsistent results but does not link to a controlled clinical trial, regulatory filings, or peer‑reviewed publications for the product itself [4]. Nowhere in the provided sources is there a clinical trial registration, journal article, or company press release describing a product‑level randomized controlled trial of a supplement called “Memo Blast,” so within the limits of these sources there is no published clinical trial for that product [4].
4. How to interpret company press releases and third‑party reviews — hidden incentives and different evidentiary standards
Company press releases and biotech news sites covering potravitug emphasize clinical milestones and progression to Phase III and may present positive framings even when endpoints are mixed (e.g., “Phase II primary endpoint miss” language appearing in industry coverage while company releases highlight biopsy‑proven resolution) — readers should note the implicit corporate and investor publicity agenda behind some releases and value independent peer‑reviewed publications and trial registries for verification [5] [1] [3]. Conversely, consumer review pages that promote supplements often use marketing language and guarantees without the methodological transparency of clinical trials, which explains why a product page claiming “attention in the market” is not equivalent to a randomized, controlled product‑level study [4].
5. Bottom line and limits of this review
Based solely on the supplied reporting, there is documented product‑level clinical trial activity for Memo Therapeutics’ potravitug (a prescription monoclonal antibody) with Phase I published and Phase II reported [2] [1] [3], but there is no evidence in these sources that any company has published a product‑level clinical trial for an over‑the‑counter brain supplement named “Memo Blast” or an identically named consumer nootropic [4]. If further confirmation is required beyond these sources, additional searches of trial registries (ClinicalTrials.gov), peer‑reviewed journals, and the supplement manufacturer’s filings or advertising claims would be necessary; the present dataset does not contain such evidence and therefore cannot confirm trials for Memo Blast.